Atezolizumab/Cobimetinib Combo Misses PFS Endpoint in BRAF V600 Wild-Type Melanoma

Source: OncLive, July 2019

The combination of atezolizumab (Tecentriq) and cobimetinib (Cotellic) did not improve progression-free survival (PFS) compared with pembrolizumab (Keytruda) in patients with previously untreated BRAF V600 wild-type melanoma, missing the primary endpoint of the phase III IMspire170 trial (NCT03273153).1

The safety profile observed with the combination regimen was consistent with the known safety profiles of each agent alone, wrote Exelixis, the manufacturer of cobimetinib, in a statement to the United States Securities and Exchange Commission.

Genentech, which manufactures atezolizumab and is the sponsor of the trial, announced that it will present the findings at an upcoming medical meeting.

read the original full article